Pub. Date : 2016 Jul
PMID : 26608382
7 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Impact of UGT2B17 Gene Deletion on the Pharmacokinetics of 17-Hydroexemestane in Healthy Volunteers. | 17-hydroexemestane | UDP glucuronosyltransferase family 2 member B17 | Homo sapiens |
| 2 | 17-Hydroexemestane, the major and biologically active metabolite of exemestane in humans, is eliminated via glucuronidation by the polymorphic UGT2B17 phase II drug-metabolizing enzyme. | 17-hydroexemestane | UDP glucuronosyltransferase family 2 member B17 | Homo sapiens |
| 3 | Previous microsomal studies have shown that UGT2B17 gene deletion affects the intrinsic hepatic clearances of 17-hydroexemestane in vitro. | 17-hydroexemestane | UDP glucuronosyltransferase family 2 member B17 | Homo sapiens |
| 4 | In this open-label study we set out to assess the effect of UGT2B17 gene deletion on the pharmacokinetics of 17-hydroexemestane in healthy female volunteers with and without UGT2B17. | 17-hydroexemestane | UDP glucuronosyltransferase family 2 member B17 | Homo sapiens |
| 5 | Our results showed that there were statistically significant differences in plasma 17-hydroexemestane AUC0- (P = .0007) and urine 17-hydroexemestane C24h (P = .001) between UGT2B17 genotype groups. | 17-hydroexemestane | UDP glucuronosyltransferase family 2 member B17 | Homo sapiens |
| 6 | Our results showed that there were statistically significant differences in plasma 17-hydroexemestane AUC0- (P = .0007) and urine 17-hydroexemestane C24h (P = .001) between UGT2B17 genotype groups. | 17-hydroexemestane | UDP glucuronosyltransferase family 2 member B17 | Homo sapiens |
| 7 | Our data suggest that UGT2B17 gene deletion influences 17-hydroexemestane pharmacokinetics in humans. | 17-hydroexemestane | UDP glucuronosyltransferase family 2 member B17 | Homo sapiens |